ReviewJournal of the American Heart Association2024

Mavacamten for Obstructive Hypertrophic Cardiomyopathy: Rationale for Clinically Guided Dose Titration to Optimize Individual Response.

Anjali T Owens et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.